Jay H Fowke1, Lauren Howard2, Gerald L Andriole3, Stephen J Freedland4. 1. Division of Epidemiology, Departments of Medicine and Department of Surgical Urology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: jay.fowke@vanderbilt.edu. 2. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA; Urology Section, Veterans Affairs Medical Center, Durham, NC, USA. 3. Division of Urology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. 4. Urology Section, Veterans Affairs Medical Center, Durham, NC, USA; Duke Prostate Center, Division of Urology, Department of Surgery and Pathology, Duke University School of Medicine, Durham, NC, USA.
Abstract
BACKGROUND: Although most studies found no association between alcohol intake and prostate cancer (PCa) risk, an analysis of the Prostate Cancer Prevention Trial found that high alcohol intake significantly increased PCa risk among men randomized to the 5α-reductase inhibitor (5-ARI) finasteride. OBJECTIVE: Determine whether alcohol affects PCa risk among men taking the 5-ARI dutasteride. DESIGN, SETTINGS, AND PARTICIPANTS: Reduction by Dutasteride of Prostate Cancer Events was a 4-yr, multicenter, randomized, double-blind, placebo-controlled trial to compare PCa after dutasteride administration (0.5mg/d) with placebo. Participants had a baseline prostate-specific antigen between 2.5 and 10.0 ng/ml and a recent negative prostate biopsy. Alcohol intake was determined by baseline questionnaire, and participants underwent a prostate biopsy to determine PCa status at 2 yr and 4 yr of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between alcohol intake and low-grade (Gleason <7) and high-grade (Gleason >7) PCa. RESULTS AND LIMITATIONS: Of 6374 participants in our analysis, approximately 25% reported no alcohol consumption, 49% were moderate drinkers (one to seven drinks per week), and 26% were heavy drinkers (more than seven drinks per week). Alcohol intake was not associated with low- or high-grade PCa in the placebo arm and was not associated with low-grade PCa among men taking dutasteride. In contrast, men randomized to dutasteride and reporting more than seven drinks per week were 86% more likely to be diagnosed with high-grade PCa (p=0.01). Among alcohol abstainers, dutasteride was associated with significantly reduced risk of high-grade PCa (OR: 0.59; 95% CI, 0.38-0.90), but dutasteride was no longer associated with reduced high-grade PCa among men reporting high alcohol intake (OR: 0.99; 95% CI, 0.67-1.45). CONCLUSIONS: Alcohol consumption negated a protective association between dutasteride and high-grade PCa. PATIENT SUMMARY: We confirmed a prior study that alcohol affects PCa prevention in patients taking 5-ARIs. Patients taking 5-ARIs may wish to eliminate alcohol intake if they are concerned about PCa.
RCT Entities:
BACKGROUND: Although most studies found no association between alcohol intake and prostate cancer (PCa) risk, an analysis of the Prostate Cancer Prevention Trial found that high alcohol intake significantly increased PCa risk among men randomized to the 5α-reductase inhibitor (5-ARI) finasteride. OBJECTIVE: Determine whether alcohol affects PCa risk among men taking the 5-ARIdutasteride. DESIGN, SETTINGS, AND PARTICIPANTS: Reduction by Dutasteride of Prostate Cancer Events was a 4-yr, multicenter, randomized, double-blind, placebo-controlled trial to compare PCa after dutasteride administration (0.5mg/d) with placebo. Participants had a baseline prostate-specific antigen between 2.5 and 10.0 ng/ml and a recent negative prostate biopsy. Alcohol intake was determined by baseline questionnaire, and participants underwent a prostate biopsy to determine PCa status at 2 yr and 4 yr of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between alcohol intake and low-grade (Gleason <7) and high-grade (Gleason >7) PCa. RESULTS AND LIMITATIONS: Of 6374 participants in our analysis, approximately 25% reported no alcohol consumption, 49% were moderate drinkers (one to seven drinks per week), and 26% were heavy drinkers (more than seven drinks per week). Alcohol intake was not associated with low- or high-grade PCa in the placebo arm and was not associated with low-grade PCa among men taking dutasteride. In contrast, men randomized to dutasteride and reporting more than seven drinks per week were 86% more likely to be diagnosed with high-grade PCa (p=0.01). Among alcohol abstainers, dutasteride was associated with significantly reduced risk of high-grade PCa (OR: 0.59; 95% CI, 0.38-0.90), but dutasteride was no longer associated with reduced high-grade PCa among men reporting high alcohol intake (OR: 0.99; 95% CI, 0.67-1.45). CONCLUSIONS:Alcohol consumption negated a protective association between dutasteride and high-grade PCa. PATIENT SUMMARY: We confirmed a prior study that alcohol affects PCa prevention in patients taking 5-ARIs. Patients taking 5-ARIs may wish to eliminate alcohol intake if they are concerned about PCa.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: M I Díaz Gómez; C Rodríguez de Castro; S L Fanelli; L N Quintans; M H Costantini; J A Castro; G D Castro Journal: J Appl Toxicol Date: 2007 Jul-Aug Impact factor: 3.446
Authors: Rosalind A Breslow; Chiung M Chen; Barry I Graubard; Tova Jacobovits; Ashima K Kant Journal: Am J Clin Nutr Date: 2013-03-27 Impact factor: 7.045
Authors: Madlen Schütze; Heiner Boeing; Tobias Pischon; Jürgen Rehm; Tara Kehoe; Gerrit Gmel; Anja Olsen; Anne M Tjønneland; Christina C Dahm; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Antonia Trichopoulou; Vasiliki Benetou; Dimosthenis Zylis; Rudolf Kaaks; Sabine Rohrmann; Domenico Palli; Franco Berrino; Rosario Tumino; Paolo Vineis; Laudina Rodríguez; Antonio Agudo; María-José Sánchez; Miren Dorronsoro; Maria-Dolores Chirlaque; Aurelio Barricarte; Petra H Peeters; Carla H van Gils; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Timothy J Key; Paolo Boffetta; Nadia Slimani; Mazda Jenab; Dora Romaguera; Petra A Wark; Elio Riboli; Manuela M Bergmann Journal: BMJ Date: 2011-04-07
Authors: Luisa Zuccolo; Sarah J Lewis; Jenny L Donovan; Freddie C Hamdy; David E Neal; George Davey Smith Journal: Int J Cancer Date: 2012-10-25 Impact factor: 7.396
Authors: Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann Journal: Rev Endocr Metab Disord Date: 2015-09 Impact factor: 6.514
Authors: Matthew G Thompson; Flor Navarro; Lennox Chitsike; Luis Ramirez; Elizabeth J Kovacs; Stephanie K Watkins Journal: Alcohol Date: 2016-10-18 Impact factor: 2.405
Authors: S Fischer; S Sun; L E Howard; D M Moreira; R Castro-Santamaria; G L Andriole; A C Vidal; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2016-03-01 Impact factor: 5.554
Authors: Ming Liu; Xiaohong Shi; Fan Yang; Jianye Wang; Yong Xu; Dong Wei; Kuo Yang; Yaoguang Zhang; Xin Wang; Siying Liang; Xin Chen; Liang Sun; Xiaoquan Zhu; Chengxiao Zhao; Ling Zhu; Lei Tang; Chenguang Zheng; Ze Yang Journal: Int J Environ Res Public Health Date: 2016-01-27 Impact factor: 3.390
Authors: Lucy E Hackshaw-McGeagh; Chris M Penfold; Eleanor Walsh; Jenny L Donovan; Freddie C Hamdy; David E Neal; Mona Jeffreys; Richard M Martin; J Athene Lane Journal: Int J Cancer Date: 2015-04-01 Impact factor: 7.396